Letrozol Almus Pharma

Letrozole, the active ingredient in Letrozol Almus Pharma, is an aromatase inhibitor presented as a tablet for oral use. It reduces estrogen production and is used to treat postmenopausal estrogen receptor‑positive breast cancer. GNH USA supplies Letrozol Almus Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is an aromatase inhibitor employed in hormone‑dependent breast cancer management. - Postmenopausal estrogen receptor‑positive breast cancer: reduces tumor growth by lowering estrogen levels. - Adjuvant therapy for early‑stage breast cancer: decreases risk of disease recurrence after surgery. - Metastatic breast cancer in postmenopausal women: helps control disease progression.

Letrozole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: mild stomach upset. - Headache: occasional throbbing pain. - Increased cholesterol: elevated lipid levels.

Serious or Rare Side Effects: - Osteoporosis: decreased bone mineral density leading to fractures. - Deep vein thrombosis: blood clot formation in veins. - Liver dysfunction: abnormal liver enzyme elevations. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Cardiovascular events: heart attack or stroke. - Vision changes: blurred vision or ocular discomfort.

Before using Letrozol Almus Pharma, consider the following precautions: - Pregnancy: contraindicated; teratogenic risk (Category X). - Breastfeeding: not recommended; drug may pass into milk. - Bone health: monitor bone mineral density, supplement calcium/vitamin D as needed. - Cardiovascular risk: assess history of heart disease before treatment. - Liver function: perform baseline liver tests and monitor periodically. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Letrozole can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2A6 inducers (e.g., rifampin): may reduce letrozole plasma levels. - Estrogen‑containing hormone therapy: antagonizes letrozole’s anti‑estrogen effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding risk; monitor INR. - Cholesterol‑lowering agents (e.g., statins): possible additive effect on liver enzymes. - CYP2A6 inhibitors (e.g., fluvoxamine): may raise letrozole concentrations. - SSRIs/SNRIs: may affect bone metabolism; monitor bone health. - Herbal supplements (e.g., St. John’s wort): potential enzyme induction; advise caution.